During the recent session, Lyell Immunopharma Inc (NASDAQ:LYEL)’s traded shares were 0.56 million, with the beta value of the company hitting -0.26. At the last check today, the stock’s price was $0.41, reflecting an intraday loss of -5.02% or -$0.02. The 52-week high for the LYEL share is $2.88, that puts it down -602.44 from that peak though still a striking 4.88% gain since the share price plummeted to a 52-week low of $0.39. The company’s market capitalization is $120.05M, and the average trade volume was 907.50K shares over the past three months.
Lyell Immunopharma Inc (LYEL) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 3.33. LYEL has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Lyell Immunopharma Inc (LYEL) registered a -5.02% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.02% in intraday trading to $0.41, hitting a weekly high. The stock’s 5-day price performance is -11.86%, and it has moved by -7.91% in 30 days. Based on these gigs, the overall price performance for the year is -84.00%.
The consensus price target of analysts on Wall Street is $7, which implies an increase of 94.14% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $12 respectively. As a result, LYEL is trading at a discount of -2826.83% off the target high and -143.9% off the low.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
In the rating firms’ projections, revenue will decrease -46.72% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -19.90%. While earnings are projected to return 43.61% in 2025, the next five years will return 21.29% per annum.
LYEL Dividends
Lyell Immunopharma Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 15.09 million shares, is of ORLAND PROPERTIES LTD’s that is approximately 5.91% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $21.89 million.
Also, the Mutual Funds coming in first place with the largest holdings of Lyell Immunopharma Inc (LYEL) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Health Sciences Fund, Inc. . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 5.64 shares. This amounts to just over 1.91 percent of the company’s overall shares, with a $2.29 million market value. The same data shows that the other fund manager holds slightly less at 4.94, or about 1.67% of the stock, which is worth about $2.0 million.
